XOMA Ltd. Deals and Alliances Profile Introduction Xoma Ltd. (Xoma) is a biopharmaceutical company engaged in the discovery, development and manufacture of therapeutic antibodies for the treatment of inflammatory, autoimmune, infectious and oncological diseases. The company leveraging its expertise, technologies, and various collaborative development programs, has developed a potential product pipeline. It currently has three approved marketable products: Raptiva, for the treatment of chronic moderate-to-severe plaque psoriasis; Lucentis, for the treatment of neovascular (wet) age-related macular degeneration; and Cimzia, for the treatment of Crohn's disease. Global Market Directs XOMA Ltd. Deals and Alliances Profile is the essential source for company data and information. The profile examines the companys key business structure and operations, history and products, as well as highlights the companys major recent financial deals. Scope Provides all the crucial company information required for business and competitor intelligence needs Gives information on the companys major recent financial deals. Data is supplemented with details on the companys history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.Reasons to Purchase Obtain up to date company information. Support sales activities by understanding your customers businesses. Qualify prospective partners and suppliers. Understand and respond to your competitors business structure, strategy and prospects.
|
